Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Accumulated Expenses (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Accumulated Expenses readings, the most recent being $3.8 million for Q4 2023.

  • On a quarterly basis, Accumulated Expenses rose 94.16% to $3.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $3.8 million, a 94.16% increase, with the full-year FY2023 number at $3.8 million, up 94.16% from a year prior.
  • Accumulated Expenses hit $3.8 million in Q4 2023 for Elicio Therapeutics, down from $4.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $6.7 million in Q4 2020 to a low of $1.1 million in Q1 2023.
  • Median Accumulated Expenses over the past 4 years was $4.1 million (2021), compared with a mean of $4.0 million.
  • The widest YoY moves for Accumulated Expenses: up 94.16% in 2023, down 78.96% in 2023.
  • Elicio Therapeutics' Accumulated Expenses stood at $6.7 million in 2020, then tumbled by 51.7% to $3.2 million in 2021, then tumbled by 39.89% to $1.9 million in 2022, then skyrocketed by 94.16% to $3.8 million in 2023.
  • The last three reported values for Accumulated Expenses were $3.8 million (Q4 2023), $4.4 million (Q3 2023), and $2.3 million (Q2 2023) per Business Quant data.